
uniQure NV
QUREHealthcare|Biotechnology|Netherlands
$42.63
-1.85 (-4.16%)
Tangible Book
$0.87
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
23.84,
72.79,
240.31,
354.77,
617.22
],
"ebit_estimate": [
-207.96,
-208.32,
-129.14,
141.19,
345.84
],
"ebitda_estimate": [
-199.82,
-166.12,
-62.83,
30.6,
462.45
],
"net_income_estimate": [
-230.24,
-227.19,
-163.38,
-86.08,
423.1
],
"per_share_eps_estimate": [
-3.56,
-3.2,
-1.86,
-0.6,
3.52
],
"eps_nri_estimate": [
-3.63,
-3.26,
-2.19,
-0.6,
3.52
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
-4.25,
-3.27,
null,
null,
null
],
"pretax_income_estimate": [
-231.25,
-231.15,
-171.71,
211.03,
318.58
],
"operating_cash_flow_per_share_estimate": [
-3.61,
-2.2,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
139.54,
64.03,
null,
null,
null
],
"gross_margin_estimate": [
85.5,
89.05,
85.25,
84.65,
83.15
],
"operating_cash_flow_estimate": [
-226.5,
-138.04,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
12.1
],
"long_term_growth_rate_mean": 13.78,
"long_term_revenue_growth_rate_mean": "151.58",
"future_per_share_eps_estimate_growth": 17.92,
"future_eps_nri_estimate_growth": 13.78,
"future_revenue_estimate_growth": 151.58,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": 27.25,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
5.47,
5.9,
6.95,
9.05,
3.9,
7.85,
16.3
],
"ebit_estimate": [
-48.63,
-56.68,
-61.62,
-72.84,
-63.2,
-64.9,
-51.6
],
"ebitda_estimate": [
-46.2,
-56.54,
-64.34,
-81.16,
null,
null,
null
],
"net_income_estimate": [
-52.39,
-60.16,
-63.83,
-64.3,
-64.3,
-66,
-52.7
],
"per_share_eps_estimate": [
-0.82,
-0.92,
-1,
-0.91,
-0.93,
-0.95,
-0.88
],
"eps_nri_estimate": [
-0.83,
-0.94,
-1.03,
-1.7,
-0.88,
-0.88,
-0.78
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-51.9,
-59.52,
-64.6,
-64.3,
-64.3,
-66,
-52.7
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 13.78,
"long_term_revenue_growth_rate_mean": "151.58",
"future_per_share_eps_estimate_growth": 17.92,
"future_eps_nri_estimate_growth": 13.78,
"future_revenue_estimate_growth": 151.58,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": 27.25,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}